Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
133.10 USD | -0.20% |
|
-0.88% | +17.52% |
02:14pm | Citigroup Adjusts Abbott Laboratories Price Target to $157 From $155, Maintains Buy Rating | MT |
03:45am | Company earnings: key dates for next week | ![]() |
Business description: Abbott Laboratories
- diagnostic systems and instruments (39.1%);
- vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
- nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products;
- medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.;
- other (15.9%).
Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Number of employees: 114,000
Sales by Activity: Abbott Laboratories
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Medical Devices | 11.79B | 14.37B | 14.69B | 16.89B | 18.99B |
Diagnostics | 10.8B | 15.64B | 16.58B | 9.99B | 9.34B |
Nutrition | 7.65B | 8.29B | 7.46B | 8.15B | 8.41B |
Established Pharmaceutical | 4.3B | 4.72B | 4.91B | 5.07B | 5.19B |
Other | 66M | 52M | 11M | 14M | 16M |
Geographical breakdown of sales: Abbott Laboratories
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
United States | 13.02B | 16.64B | 18.14B | 15.45B | 16.32B |
All Other Countries | 12.58B | 15.52B | 14.84B | 14.08B | 14.85B |
Germany | 2.11B | 2.57B | 2.34B | 2.34B | 2.54B |
China | 1.96B | 2.39B | 2.13B | 2.25B | 2.11B |
India | 1.32B | 1.56B | 1.65B | 1.75B | 1.82B |
Switzerland | 1.14B | 1.31B | 1.34B | 1.64B | 1.75B |
Japan | 1.39B | 1.7B | 1.93B | 1.51B | 1.44B |
The Netherlands | 1.08B | - | - | 1.07B | 1.12B |
Canada | - | 1.38B | 1.28B | - | - |
Executive Committee: Abbott Laboratories
Manager | Title | Age | Since |
---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 51 | 2020-03-30 |
Philip Boudreau
DFI | Director of Finance/CFO | 52 | 2023-08-31 |
Sabina Ewing
CIO | Chief Investment Officer | 50 | - |
Scott House
CTO | Chief Tech/Sci/R&D Officer | - | 2020-02-29 |
Melissa Brotz
SAM | Sales & Marketing | - | - |
Composition of the Board of Directors: Abbott Laboratories
Director | Title | Age | Since |
---|---|---|---|
Robert Alpern
BRD | Director/Board Member | 74 | 2008-10-09 |
Sally Blount
BRD | Director/Board Member | 63 | 2011-12-08 |
Nancy McKinstry
BRD | Director/Board Member | 66 | 2011-12-08 |
Daniel Starks
BRD | Director/Board Member | 70 | 2017-02-15 |
John Stratton
BRD | Director/Board Member | 64 | 2017-06-28 |
Robert Ford
CHM | Chairman | 51 | 2021-12-09 |
Michelle Kumbier
BRD | Director/Board Member | 57 | 2018-06-07 |
Darren McDew
BRD | Director/Board Member | 64 | 2019-09-08 |
Michael Roman
BRD | Director/Board Member | 65 | 2021-04-22 |
Paola Gonzalez
BRD | Director/Board Member | 53 | 2021-08-29 |
Holdings: Abbott Laboratories
Name | Equities | % | Valuation |
---|---|---|---|
ABBOTT INDIA LIMITED 74.99% | 15,934,048 | 74.99% | 6,621,371,498 $ |
76,259,451 | 77.9% | 260,052,354 $ | |
17,949,800 | 51.69% | 42,743,320 $ | |
2,061,855 | 4.74% | 2,230,515 $ |
Company details: Abbott Laboratories

Group companies: Abbott Laboratories
Name | Category and Sector |
---|---|
TwistDx Ltd.
![]() TwistDx Ltd. BiotechnologyHealth Technology Part of Abbott Laboratories, TwistDx Ltd. is a British company that specializes in recombinase polymerase amplification technology. The company is based in Maidenhead, UK. The company offers TwistAmp research kits for researchers to develop tests, assays, and kits relevant to their work in fields such as water testing, biodefense, food species verification, and clinical or veterinary diagnostics. The company can work with partners on specific assay development collaborations for research and commercial applications. The company offers devices and accessories for research and development use only. The company was founded in 2002 by Niall Armes, Derek Stemple, Nagesh K. Mahanthappa. |
Biotechnology
|
Abbott Laboratórios do Brasil Ltda.
![]() Abbott Laboratórios do Brasil Ltda. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, Abbott Laboratórios do Brasil Ltda. is a company based in São Paulo, Brazil. The Brazilian company conducts innovative research and develops products for human health at all stages of life. Recently, Abbott has launched new products that have the power to change lives. The company's website includes a privacy policy that outlines the definition, collection, and use of personal information. Learn more about Abbott, the personal health company. |
Pharmaceuticals: Major
|
Abbott Laboratories de Chile Ltda.
![]() Abbott Laboratories de Chile Ltda. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Abbott Laboratories de Chile Ltda. The company is based in Las Condes, Chile. is a Chilean company that engages in diagnostics, medical devices, nutritional, and branded generic medicines. |
Medical Specialties
|
Abbott Overseas Luxembourg SARL
![]() Abbott Overseas Luxembourg SARL Financial ConglomeratesFinance Part of Abbott Laboratories, Abbott Overseas Luxembourg SARL is a company that provides investment services. The company is based in Luxembourg, Luxembourg. |
Financial Conglomerates
|
Abbott AG |
Medical Specialties
|
Other Medical Equipment, Supplies & Distribution
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.35% | -0.99% | +30.64% | +21.94% | 232B | ||
+0.15% | +0.50% | +15.40% | -0.26% | 113B | ||
+0.06% | +2.46% | +34.16% | +111.11% | 57.77B | ||
+0.21% | -1.20% | -20.91% | -28.13% | 50.05B | ||
+1.09% | +3.45% | -11.96% | +41.19% | 39.78B | ||
+0.99% | +1.18% | -23.70% | +7.83% | 32.84B | ||
+0.92% | -4.67% | -9.45% | +19.05% | 24.69B | ||
-0.50% | -2.29% | +27.64% | -41.63% | 22.94B | ||
-0.77% | -3.07% | +8.16% | +10.45% | 22.88B | ||
+0.29% | -1.23% | +52.64% | +29.06% | 20.87B | ||
Average | +0.20% | -1.13% | +10.26% | +17.06% | 61.73B | |
Weighted average by Cap. | +0.03% | -0.88% | +16.55% | +19.97% |
Sector

Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABT Stock
- Company Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions